Bavarian Nordic A/S announced that the Swiss Federal Office of Public Health and the Swiss Armed Forces have jointly ordered 100,000 doses of MVA-BN smallpox and monkeypox vaccine. First deliveries will start imminently, and final deliveries will occur in early 2023.
As part of the agreement, Bavarian Nordic will submit an application to Swissmedic within three months to support a potential marketing authorization of the vaccine against smallpox and monkeypox in 2023.
Given the magnitude of the order and the delivery schedule this will not impact the financial guidance for 2022.
Paul Chaplin, President and CEO of Bavarian Nordic said: “As the epicenter of the outbreak, Europe has seen a wide spread of monkeypox as well as a high number of cases in many countries. Thankfully, the case numbers are now going down, but efforts are still required to end the outbreak and hopefully preventing the disease becoming endemic in the region. We are therefore pleased to enter this agreement with the Swiss authorities, complementing the efforts by the EU Commission to provide access to the vaccine for at-risk populations across the entire region.”